Caliper Unit Xenogen Pens Target Validation Deal With Schering-Plough
Caliper Life Sciences business unit Xenogen Biosciences will collaborate with Schering-Plough Research Institute to validate targets in drug discovery, Xenogen said this week.
Xenogen will use its serial phenotyping compression technology to characterize high-value targets, it said. The technology relies on a battery of more than 85 pharmacologically validated bioassays.
The agreement expands on a previous gene-targeting agreement to create standard and conditional gene knockouts, the company said.
Caliper Life Sciences announced it would acquire Xenogen Biosciences in February, and closed the deal on Aug. 9.
Financial details of the agreement were not disclosed.
Evotec Receives More than $1.3M for Takeda Alzheimer’s Milestone
Evotec this week said that it has achieved a second milestone payment worth over €1 million ($1.27 million) in its four-year drug-discovery collaboration with Japanese drug firm Takeda.
Evotec has granted Takeda exclusive rights to a novel target in Alzheimer’s disease based on successful target ID and validation work, which triggered the milestone payment.
Evotec said it is eligible for “substantial” future milestones based on the successful clinical development of compounds acting on the target.